An identity crisis for fps/fes: Oncogene or tumor suppressor?

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3518-3522

  Sangrar, Waheed ^a,b   Zirgnibl, Ralph A ^a,b   Gao, Yan ^a   Muller, William J ^c   Jia, Zongchao ^b   Greer, Peter A ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PHOSPHOTRANSFERASE; PROTEIN KINASE FES; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; COLORECTAL CANCER; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROVIRUS; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ENZYME ACTIVATION; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, MOLECULAR; MUTATION; ONCOGENES; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FES;

EID: 18144423495     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3468     Document Type: Article

References (21)

1. Smithgall TE, Rogers JA, Peters KL, et al. The c-Fes family of protein-tyrosine kinases. Crit Rev Oncog 1998;9:43-62.
2. Greer PA. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 2002;3:278-89.
3. Yee SP, Mock D, Greer P, et al. Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase. Mol Cell Biol 1989;9:5491-9.
4. Cheng HY, Schiavone AP, Smithgall TE. A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells. Mol Cell Biol 2001;21:6170-80.
5. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949.
6. Senis Y, Zirngibl R, McVeigh J, et al. Targeted disruption of the murine fps/fes proto-oncogene reveals that Fps/Fes kinase activity is dispensable for hematopoiesis. Mol Cell Biol 1999;19:7436-46.
7. Greer P, Maltby V, Rossant J, Bernstein A, Pawson T. Myeloid expression of the human c-fps/fes protooncogene in transgenic mice. Mol Cell Biol 1990;10:2521-7.
8. Zirngibl RA, Senis Y, Greer PA. Enhanced endotoxin-sensitivity in Fps/Fes-null mice with minimal defects in hematopoietic homeostasis. Mol Cell Biol 2002;22:2472-86.
9. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
10. Craig AW, Zirngibl R, Greer P. Disruption of coiled-coil domains in Fer protein-tyrosine kinase abolishes trimerization but not kinase activation. J Biol Chem 1999;274:19934-42.
11. Williams JC, Weijland A, Gonfloni S, et al. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J Mol Biol 1997;274:757-75.
12. Scott WRP, Hunenberger PH, Tironi IG, et al. The GROMOS biomolecular simulation program package. J Phys Chem A 1999;103:3596-607.
13. Kraulis P. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991;24:946-50.
14. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
15. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2002;2:951-6.
16. Moroni M, Soldatenkov V, Zhang L, et al. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 2004;64:7346-54.
17. Read RD, Bach EA, Cagan RL. Drosophila C-terminal Src kinase negatively regulates organ growth and cell proliferation through inhibition of the Src, Jun N-terminal kinase, and STAT pathways. Mol Cell Biol 2004;24:6676-89.
18. Huusko P, Ponciano-Jackson D, Wolf M, et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 2004;36:979-83.
19. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994;8:23-32.
20. Wheelock MJ, Soler AP, Knudsen KA. Cadberin junctions in mammary tumors. J Mammary Gland Biol Neoplasia 2001;6:275-85.
21. Xu G, Craig AW, Greer P, et al. Continuous association of cadherin with β-catenin requires the non-receptor tyrosine-kinase Fer. J Cell Sci 2004;117:3207-19.